* MediciNova Inc MNOV.OQ MNOV.O is expected to show a
fall in
quarterly revenue when it reports results on May 11
(estimated).
* Refinitiv's mean analyst estimate for MediciNova Inc is
for a
loss of 9 cents per share. For the same quarter last year, the
company reported breakeven results per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for MediciNova
Inc is
$12, above its last closing price of $2.51.
This summary was machine generated May 9 at 12:50 GMT. All
figures in US dollars unless otherwise stated